Company: MDCXW
Filing Date: 2025-09-11
Form Type: DRS
Source: 0001062993-25-015568
Chunk: 234

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-11
Form: DRS
Chunk 234
---
 net proceeds from sales, if any, under the SEPA, will depend on the frequency and prices at which we sell common shares to the Selling Shareholder after the date of this prospectus.

Thesaleof the common shares offered by thisprospectus could be effected inone or more of the following methods:

ordinarybrokers'transactions;

transactions involving cross or block trades;

through brokers, dealers, or underwriters who may act solely as agents;

"atthe market" into an existing market for our common shares;

in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;

inprivatelynegotiated transactions;or

anycombination of the foregoingor anymanner permitted under applicable law.

In order to comply with the securities laws ofcertainstates, if applicable, theshares may be soldonly through registered or licensed brokers or dealers.

In addition, incertain states,the common shares may not be sold unless they have been registered or qualified for salein the stateor an exemption fromthe state'sregistration or qualificationrequirementis available andcomplied with.

TheSelling Shareholder is an "underwriter" within the meaning of Section 2(a)(11) of the Securities Act.

The Selling Shareholder has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our common shares that it may acquire from us pursuant to the SEPA. Such sales will be made at prices then prevailing or at prices related to the then-current market price. Such registered broker-dealer may, in some circumstances (for instance, if such registered broker-dealer's involvement is not limited to receiving commission not in excess of the usual and customary distributors' or sellers' commissions), be considered to be an underwriterwithin the meaning of Section 2(a)(11) of the Securities Act.The Selling Shareholder has informed us that each such broker-dealer may receive commissions from the Selling Shareholder for executing such sales for the Selling Shareholder and, if so, such commissions will not exceed customary brokerage commissions.

Brokers, dealers, underwriters, or agents participating in the distribution of our common shares offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Shareholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of common shares sold by